|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, September 14, 2011 ) Belize City, Belize: ViorraTM product launch closer than you think
Reading between the lines in the press release today tells that company is close to product launch – with updates soon at hand!
"North American clinical safety trials do not necessarily imply Easton cannot proceed to the launch of VIORRA in various other markets outside of North America where such safety tests are not required prior to any marketing of the product including Mexico and other Latin American and East Asian markets."
This statement says it allÂ…with the company breaking silence silence since August 2nd, this press release is no random update. Expect some significant updates on distribution outside of North America, and the companyÂ’s patent fairly soon.
EAPH closed at $0.075 a minor pause to re-group from over 200% gains since Friday’s alert – with more significant updates comes higher prices. As with any of xtremepicks.com's long term plays, buy on the dips and hold for long term mega gains.
Easton Pharmaceuticals to Enter Into Clinical Safety Trials of VIORRA for North American Market
Easton Pharmaceuticals Inc a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced today the company is in the process of formalizing a plan to enter into North American clinical trials of VIORRA as a precursor to future North American product launch.
Easton is formulating a strategy to undertake additional clinical trials, which involves entering into an estimated 6 month clinical trial program at various well established clinic(s) within North America. EastonÂ’s highly skilled team of doctors and consultants shall provide input into the scope and process including the various clinics being contemplated for the trials. The total scale and depth of the trials are dependant on various factors including sufficient capital to fully complete a well detailed trial and analysis on all possible safety issues prior to any marketing of the product in North America.
Any North American clinical safety trials do not necessarily imply Easton cannot proceed to the launch of VIORRA in various other markets outside of North America where such safety tests are not required prior to any marketing of the product including Mexico and other Latin American and East Asian markets. Such foreign markets possess their own internal requirements which are independent of any North American standards.
Easton Pharmaceuticals has previously undertaken various clinical trials of VIORRA and obtained positive efficacy results which has led the company to believe it would act as an effective over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity promoting a positive effect on womenÂ’s sexual desire and arousal FSAD (Female Sexual Arousal Disorder). VIORRA is a topical, daily-use product formulated with ingredients classified by the FDA as (GRAS) Generally Recognized as Safe.
ABOUT EAPH – EASTON PHARMACEUTICALS
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops and markets a range of premium, topically delivered therapeutic health care products. The companyÂ’s proprietary gel formulation is an innovative and unique transdermal delivery system.
The system is the technology that allows for the rapid development of non-invasive, naturally derived topical solutions that have the ability to revitalize and stimulate the healing of a variety of skin and tissue conditions. The transdermal delivery system allows for the targeted delivery of active ingredients, vitamins and herbs through the skin to the underlying tissue.
The company has utilized its transdermal delivery system to develop a safe and effective female sexual enhancement product. The companyÂ’s goal is to develop a portfolio of topical pharmaceutical and cosmeceutical products targeting various skin and tissue conditions including: scars and stretch marks, cellulite and varicose veins.
Xtremepicks.com your trading connection and remember to always do your own research, use stop loss orders to protect yourself, and book your profits when in a position to do so.
Xtremepicks.com profiles are not a solicitation or recommendation to buy, sell or hold securities and is not offering securities for sale. Verify all claims and do your own due diligence. Xtremepicks received $20K for a 2 week profile of EAPH from Direct Global Media and at times may buy EAPH in the open market. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Click here to view the full disclaimer
Directglobalmedia.com
Max Gordon
6479227508
contact@directglobalmedia.com 
Source: EmailWire.com
|
|
|
|
